Steminent Biotherapeutics Inc.
7729StockTWO
78.70 ▲ +4.79%
12 juin 2026
7
Steminent Biotherapeutics Inc.
78.70 ▲ +4.79%
12 juin 2026
7729StockTWO

01 / À propos

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

Arberion
Loading market data